Synlogic (STU:MIN) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MIN Synlogic Inc STU:MIN
30 GF Score
Price €3.63
GF Value €0.15
! 1 Warning Sign
View Full Analysis

What is Synlogic Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:MIN
30GF Score
Synlogic Inc STU:MIN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Synlogic (STU:MIN) Overvalued in 2026?

Based on GuruFocus' analysis, Synlogic stock appears to be overvalued. The current stock price of €3.63 is trading 2320% above its estimated GF Value™ of €0.15.

Key valuation signals for STU:MIN:

  • Short Ratio:
  • GF Value™: €0.15 vs. price of €3.63 (2320% above fair value)
  • GF Score™: 30/100 with 1 warning sign

No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synlogic Business Description

Other Exchanges SYBX:USA0A8U:UK
Address PO Box 30, Winchester, MA, USA, 01890
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
30GF Score

Get the complete analysis for STU:MIN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.63
Price
€0.15
GF Value